ClinicalTrials.gg
CompletedNCT05027802PIVOINEUpdated Jun 22, 2025Results posted

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

A Phase 3 interventional study of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP), sponsored by Ipsen. Completed at 13 sites in 10 countries. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Myositis Ossificans by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Myositis Ossificans · Ipsen.

Started
2022
the only one that year
Phase 3
2 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Myositis Ossificans by Ipsen, this one is the only one that started in 2022, is one of 2 in phase 3, and was the 8th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

1 of the 10 studies in Myositis Ossificans by Ipsen is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myositis Ossificans by Ipsen, or all of them as a file.
02

Study summary

The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP.

The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.

03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva (FOP)

Browse trials for

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has completed the EOS or End of Treatment Visit of Study PVO-1A-301 or PVO-1A-202 (PVO-1A-202 Parts C and D correspond to Study PVO-1A-204 in France) and did not previously withdraw consent from any of the parent studies to be eligible for Study CLIN-60120-452.
  • Participant must be ≥14 years of age (aligned with the age of treated participants in the ongoing parent studies PVO-1A-301 and PVO-1A-202/PVO-1A-204) and qualify as 100% skeletally mature (if \<18 years, based on assessments carried out at parent EOS Visit; if ≥18 years, automatically considered 100% skeletally mature) or have reached final adult height based on investigator's assessment, at the time the Study CLIN- 60120-452 is signed.

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to retinoids, gelatin, lactose (note that lactose intolerance is not exclusionary) or palovarotene, or unresponsiveness to prior treatment with palovarotene.
  • Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.
  • Symptomatic vertebral fracture.
  • Intercurrent known or suspected non-healed fracture at any location;
  • Any other medical condition/ abnormalities that would expose the participant to undue risk or interfere with study assessments.
  • Amylase or lipase >2× above the (ULN) or with a history of chronic pancreatitis.
  • Elevated (AST) or alanine aminotransferase (ALT) >2.5× ULN.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • Current use of vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.
  • Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the Inclusion Visit.
  • Concurrent treatment with tetracycline or any tetracycline derivatives due to the potential increased risk of pseudotumor cerebri.
  • Use of concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.
  • Palovarotene is reimbursed in the country where the study is being conducted.
  • Any reason that, in the opinion of the investigator, would lead to the inability of the participant and/or family to comply with the protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Palovarotene Chronic/Flare-Up Regimen

    Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment. Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days.

    Drug: Palovarotene

Interventions

  • Palovarotene will be taken orally once daily at approximately the same time each day.

06

What researchers measure

Primary outcomes

  1. Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or significant medical event. A TEAE was defined as any AE that occurred after signing the informed consent form of this study or an ongoing AE from the parent study with a worsening in severity or relationship to the study treatment following transition to this study.

    Time frame: From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months

Secondary outcomes

  1. Change From the Inclusion Visit in Cumulative Analogue Joint Involvement Scale (CAJIS) Total Score at Months 6, 12, 18, 24 and 30

    The CAJIS is an objective measure of joint movement completed by the investigator to document total joint involvement. This scale assesses functional disability by categorizing range of motion across 12 joints (both right and left shoulder, elbow, wrist, hip, knee and ankle joints) and 3 body regions (cervical spine, thoracic/lumbar spine and jaw), with each joint/region assessed as: 0=normal (\<10% deficit); 1=partially impaired (10% to 90% deficit) and 2=functionally ankylosed (\>90% deficit). The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). Higher score indicated worse outcome. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  2. Change From the Inclusion Visit in the Use of Assistive Devices and Adaptations (Aids) for Daily Living at Months 6, 12, 18, 24 and 30

    The use of assistive devices and adaptations (aids) for daily living was collected using the FOP assistive devices assessment at each visit. Assistive devices and adaptations include mobility aids, eating tools, personal care tools, bathroom aids and devices, bedroom aids and devices, home adaptions, work environment adaptions, technology adaptions, sports and recreation adaptions, school adaptions and medical therapies for daily living. The mean of total number of assistive devices and adaptations for daily living being used is presented. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  3. Change From the Inclusion Visit in Percentage of Worst Score Using the Adult Form of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ) at Months 6, 12, 18, 24 and 30

    The FOP-PFQ is a disease-specific patient-reported outcome measure of physical impairment; includes 28 questions related to activities of daily living and physical performance scored on a scale of 1 to 5 with lower scores indicating that participant has more difficulty completing those tasks. Total score, upper extremities subscore and mobility subscore is calculated as follows: total score: sum of the scores from each question (range 28 to 140); upper extremities subscore: sum of the scores from 15 questions (questions 1-12, 14, 25 and 26; range 15 to 75); mobility subscore: the sum of the scores from 13 questions (questions 13, 15-24, 27 and 28; range 13 to 65). The scores were transformed to reflect a percentage of worst score which ranged from 0% to 100% with 0% indicating the best possible function and 100% (higher score) indicating the worst possible function. Mean is presented. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  4. Annualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva

    Annualized HU rate was defined as the (number of HU during the study/duration of participant participation in the study in days) \* 365.25. Annualized rate for total health care services utilized is presented.

    Time frame: Up to approximately 32 months

  5. Change From the Inclusion Visit in Percent Predicted Forced Vital Capacity (FVC) at Months 6, 12, 18, 24 and 30

    Lung function parameters including FVC were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  6. Change From the Inclusion Visit in Percent Predicted Forced Expiratory Volume in One Second (FEV1) at Months 6, 12, 18, 24 and 30

    Lung function parameters including FEV1 were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  7. Change From the Inclusion Visit in Predicted FEV1/FVC Ratio at Months 6, 12, 18, 24 and 30

    The ratio of FEV1 to FVC was calculated. Lung function parameters were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  8. Change From the Inclusion Visit in Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) at Months 6, 12, 18, 24 and 30

    The DLCO test provides information on the efficiency of gas transfer from alveolar air into the bloodstream. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  9. Change From the Inclusion Visit in Physical and Mental Function Using Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Months 6, 12, 18, 24 and 30

    The PROMIS Global Health Scale is a patient-reported outcome measure of physical and mental function. The adult form (developed for participants \>=15 years old) was used for all participants,consists of 10 questions from which 2 scores are calculated: global physical health score (GPH) and global mental health (GMH) score, each ranging from 4 (worse health) to 20 (better health). GPH score:sum of scores from Questions 3, 6, 7 and 8 and GMH score:sum of scores from Questions 2, 4, 5 and 10.These scores were converted to a T-score whose distributions were standardized such that value of 50 represented average (mean) for general population and increments of +/- 10 points represented +/- 1 standard deviation away from the norm.Higher T-scores indicated better physical/mental health. A T-score \<50 indicated worse health than general population, while a T-score \>50 indicated better health. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.

    Time frame: Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30

  10. Number of Participants With Flare-ups and Flare-up Outcomes

    Number of participants with at least 1 flare-up and intercurrent flare-ups since last visit is presented. Intercurrent flare-ups were defined as a new flare-up or marked worsening of the original flare up at any time during a flare-up-based treatment cycle. Outcome of flare-ups resulting in movement restriction and bone formations in participants is presented. Movement restriction includes categories like better, same, slightly worse, moderately worse and severely worse movement than before.

    Time frame: Months 6, 12, 18 and 24

  11. Number of Participants With Flare-ups by Body Location

    Number of participants with flare-ups by body locations including shoulder, elbow, hip, knee, ankle or foot, back, jaw and submandibular area and other (includes all other locations than mentioned) is presented.

    Time frame: Months 6, 12, 18 and 24

  12. Duration of Flare-up at Months 6, 12, 18 and 24

    Duration of flare-up was defined as (date of end of flare-up - date of start of flare-up + 1).

    Time frame: Months 6, 12, 18 and 24

  13. Percentage of Participants With Extra Bone Growth at Months 6, 12, 18 and 24

    Percentage of participants with at least 1 extra bone growth associated or not with a flare-up since last visit is presented.

    Time frame: Months 6, 12, 18 and 24

07

Results

Posted Jun 13, 2025

Participant flow

This single-arm, rollover, multicenter, Phase III, open-label study was conducted at 12 investigational sites in 9 countries from 14-Mar-2022 to 30-Nov-2024 in participants \>=14 years with fibrodysplasia ossificans progressiva (FOP) who had completed parent study PVO-1A-301 (NCT03312634) or PVO-1A-202 (NCT02279095)/PVO-1A-204 (NCT02979769) and continued to benefit from palovarotene therapy. A total of 61 participants were enrolled in the study of which 59 received treatment.

Participant flow — Overall Study
MilestonePalovarotene
Started61
Received treatment59
Completed38
Not completed23
Withdrew: Adverse event2
Withdrew: Withdrawal by subject18
Withdrew: Death2
Withdrew: Other1

Outcome measures

PrimaryNumber of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or significant medical event. A TEAE was defined as any AE that occurred after signing the informed consent form of this study or an ongoing AE from the parent study with a worsening in severity or relationship to the study treatment following transition to this study.

Time frame:
From signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months
Reported as:
Count of participants · Participants
Number of Participants With All Treatment-emergent Adverse Events (TEAEs), Serious and Non-serious Treatment-emergent Adverse Events and Serious and Non-serious Treatment-related Treatment-emergent Adverse Events
ParticipantsPalovarotene
All TEAEs54
Serious TEAEs9
Non-serious TEAEs53
Serious treatment-related TEAEs1
Non-serious treatment-related TEAEs38
SecondaryChange From the Inclusion Visit in Cumulative Analogue Joint Involvement Scale (CAJIS) Total Score at Months 6, 12, 18, 24 and 30

The CAJIS is an objective measure of joint movement completed by the investigator to document total joint involvement. This scale assesses functional disability by categorizing range of motion across 12 joints (both right and left shoulder, elbow, wrist, hip, knee and ankle joints) and 3 body regions (cervical spine, thoracic/lumbar spine and jaw), with each joint/region assessed as: 0=normal (\<10% deficit); 1=partially impaired (10% to 90% deficit) and 2=functionally ankylosed (\>90% deficit). The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved). Higher score indicated worse outcome. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · score on a scale
Change From the Inclusion Visit in Cumulative Analogue Joint Involvement Scale (CAJIS) Total Score at Months 6, 12, 18, 24 and 30
score on a scalePalovarotene
Month 60.6 ± 1.3
Month 121.1 ± 2.0
Month 181.5 ± 2.3
Month 241.5 ± 2.6
Month 302.0 ± 4.7
SecondaryChange From the Inclusion Visit in the Use of Assistive Devices and Adaptations (Aids) for Daily Living at Months 6, 12, 18, 24 and 30

The use of assistive devices and adaptations (aids) for daily living was collected using the FOP assistive devices assessment at each visit. Assistive devices and adaptations include mobility aids, eating tools, personal care tools, bathroom aids and devices, bedroom aids and devices, home adaptions, work environment adaptions, technology adaptions, sports and recreation adaptions, school adaptions and medical therapies for daily living. The mean of total number of assistive devices and adaptations for daily living being used is presented. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · number of aids
Change From the Inclusion Visit in the Use of Assistive Devices and Adaptations (Aids) for Daily Living at Months 6, 12, 18, 24 and 30
number of aidsPalovarotene
Month 6-0.7 ± 3.4
Month 121.1 ± 4.7
Month 181.4 ± 5.7
Month 241.2 ± 5.1
Month 302.8 ± 7.4
SecondaryChange From the Inclusion Visit in Percentage of Worst Score Using the Adult Form of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ) at Months 6, 12, 18, 24 and 30

The FOP-PFQ is a disease-specific patient-reported outcome measure of physical impairment; includes 28 questions related to activities of daily living and physical performance scored on a scale of 1 to 5 with lower scores indicating that participant has more difficulty completing those tasks. Total score, upper extremities subscore and mobility subscore is calculated as follows: total score: sum of the scores from each question (range 28 to 140); upper extremities subscore: sum of the scores from 15 questions (questions 1-12, 14, 25 and 26; range 15 to 75); mobility subscore: the sum of the scores from 13 questions (questions 13, 15-24, 27 and 28; range 13 to 65). The scores were transformed to reflect a percentage of worst score which ranged from 0% to 100% with 0% indicating the best possible function and 100% (higher score) indicating the worst possible function. Mean is presented. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · percentage of score
Change From the Inclusion Visit in Percentage of Worst Score Using the Adult Form of the Fibrodysplasia Ossificans Progressiva Physical Function Questionnaire (FOP-PFQ) at Months 6, 12, 18, 24 and 30
percentage of scorePalovarotene
Month 6: total score0.74 ± 6.37
Month 12: total score2.39 ± 10.21
Month 18: total score4.77 ± 12.39
Month 24: total score7.80 ± 15.15
Month 30: total score13.79 ± 21.98
Month 6: upper extremities subscore0.70 ± 6.87
Month 12: upper extremities subscore1.12 ± 8.52
Month 18: upper extremities subscore3.24 ± 11.28
Month 24: upper extremities subscore5.54 ± 12.42
Month 30: upper extremities subscore8.15 ± 11.50
Month 6: mobility subscore0.74 ± 9.15
Month 12: mobility subscore3.90 ± 14.98
Month 18: mobility subscore6.53 ± 17.45
Month 24: mobility subscore10.38 ± 23.08
Month 30: mobility subscore20.30 ± 36.44
SecondaryAnnualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva

Annualized HU rate was defined as the (number of HU during the study/duration of participant participation in the study in days) \* 365.25. Annualized rate for total health care services utilized is presented.

Time frame:
Up to approximately 32 months
Reported as:
Mean · HU per participant year
Annualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva
HU per participant yearPalovarotene
Annualized Rate of Healthcare Utilization (HU) in Participants With Fibrodysplasia Ossificans Progressiva21.7 ± 31.4
SecondaryChange From the Inclusion Visit in Percent Predicted Forced Vital Capacity (FVC) at Months 6, 12, 18, 24 and 30

Lung function parameters including FVC were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · percent predicted FVC
Change From the Inclusion Visit in Percent Predicted Forced Vital Capacity (FVC) at Months 6, 12, 18, 24 and 30
percent predicted FVCPalovarotene
Month 61.2 ± 5.5
Month 12-0.7 ± 6.8
Month 18-3.9 ± 9.8
Month 24-1.6 ± 5.8
Month 30-2.8 ± 3.8
SecondaryChange From the Inclusion Visit in Percent Predicted Forced Expiratory Volume in One Second (FEV1) at Months 6, 12, 18, 24 and 30

Lung function parameters including FEV1 were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · percent predicted FEV1
Change From the Inclusion Visit in Percent Predicted Forced Expiratory Volume in One Second (FEV1) at Months 6, 12, 18, 24 and 30
percent predicted FEV1Palovarotene
Month 61.8 ± 5.9
Month 12-3.1 ± 9.6
Month 18-5.3 ± 11.8
Month 24-3.8 ± 6.6
Month 30-10.0 ± 11.1
SecondaryChange From the Inclusion Visit in Predicted FEV1/FVC Ratio at Months 6, 12, 18, 24 and 30

The ratio of FEV1 to FVC was calculated. Lung function parameters were obtained by spirometry. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · ratio
Change From the Inclusion Visit in Predicted FEV1/FVC Ratio at Months 6, 12, 18, 24 and 30
ratioPalovarotene
Month 60.0163 ± 0.0574
Month 12-0.0323 ± 0.1358
Month 18-0.0137 ± 0.0888
Month 24-0.0365 ± 0.0994
Month 30-0.1268 ± 0.1564
SecondaryChange From the Inclusion Visit in Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) at Months 6, 12, 18, 24 and 30

The DLCO test provides information on the efficiency of gas transfer from alveolar air into the bloodstream. The Inclusion Visit was the first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · percent predicted DLCO
Change From the Inclusion Visit in Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) at Months 6, 12, 18, 24 and 30
percent predicted DLCOPalovarotene
Month 6-1.5 ± 7.9
Month 12-5.3 ± 12.6
Month 18-4.4 ± 16.5
Month 24-4.8 ± 11.4
Month 30-20.0 ± 20.3
SecondaryChange From the Inclusion Visit in Physical and Mental Function Using Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Months 6, 12, 18, 24 and 30

The PROMIS Global Health Scale is a patient-reported outcome measure of physical and mental function. The adult form (developed for participants \>=15 years old) was used for all participants,consists of 10 questions from which 2 scores are calculated: global physical health score (GPH) and global mental health (GMH) score, each ranging from 4 (worse health) to 20 (better health). GPH score:sum of scores from Questions 3, 6, 7 and 8 and GMH score:sum of scores from Questions 2, 4, 5 and 10.These scores were converted to a T-score whose distributions were standardized such that value of 50 represented average (mean) for general population and increments of +/- 10 points represented +/- 1 standard deviation away from the norm.Higher T-scores indicated better physical/mental health. A T-score \<50 indicated worse health than general population, while a T-score \>50 indicated better health. Inclusion Visit was first study visit (Day 1) and first administration of palovarotene in this study.

Time frame:
Inclusion Visit (Day 1) and Months 6, 12, 18, 24 and 30
Reported as:
Mean · T-score
Change From the Inclusion Visit in Physical and Mental Function Using Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale at Months 6, 12, 18, 24 and 30
T-scorePalovarotene
Month 6: GPH-0.6 ± 4.4
Month 12: GPH-1.7 ± 5.0
Month 18: GPH-2.9 ± 5.0
Month 24: GPH-1.9 ± 5.8
Month 30: GPH-3.9 ± 7.0
Month 6: GMH-1.0 ± 4.8
Month 12: GMH-1.5 ± 6.3
Month 18: GMH-2.3 ± 6.9
Month 24: GMH-2.2 ± 6.0
Month 30: GMH-5.7 ± 5.1
SecondaryNumber of Participants With Flare-ups and Flare-up Outcomes

Number of participants with at least 1 flare-up and intercurrent flare-ups since last visit is presented. Intercurrent flare-ups were defined as a new flare-up or marked worsening of the original flare up at any time during a flare-up-based treatment cycle. Outcome of flare-ups resulting in movement restriction and bone formations in participants is presented. Movement restriction includes categories like better, same, slightly worse, moderately worse and severely worse movement than before.

Time frame:
Months 6, 12, 18 and 24
Reported as:
Count of participants · Participants
Number of Participants With Flare-ups and Flare-up Outcomes
ParticipantsPalovarotene
Month 6: at least 1 flare up since last visit27
Month 12: at least 1 flare up since last visit26
Month 18: at least 1 flare up since last visit15
Month 24: at least 1 flare up since last visit4
Month 6: intercurrent flare-ups since last visit7
Month 12: intercurrent flare-ups since last visit4
Month 18: intercurrent flare-ups since last visit4
Month 24: intercurrent flare-ups since last visit0
Month 6: better movement0
Month 6: same movement22
Month 6: slightly worse movement7
Month 6: moderately worse movement5
Month 6: severely worse movement1
Month 12: better movement1
Month 12: same movement17
Month 12: slightly worse movement10
Month 12: moderately worse movement5
Month 12: severely worse movement0
Month 18: better movement0
Month 18: same movement7
Month 18: slightly worse movement7
Month 18: moderately worse movement1
Month 18: severely worse movement1
Month 24: better movement0
Month 24: same movement1
Month 24: slightly worse movement3
Month 24: moderately worse movement0
Month 24: severely worse movement1
Month 6: bone formation5
Month 12: bone formation5
Month 18: bone formation1
Month 24: bone formation0
SecondaryNumber of Participants With Flare-ups by Body Location

Number of participants with flare-ups by body locations including shoulder, elbow, hip, knee, ankle or foot, back, jaw and submandibular area and other (includes all other locations than mentioned) is presented.

Time frame:
Months 6, 12, 18 and 24
Reported as:
Count of participants · Participants
Number of Participants With Flare-ups by Body Location
ParticipantsPalovarotene
Month 6: shoulder8
Month 6: elbow3
Month 6: hip5
Month 6: knee5
Month 6: ankle or foot3
Month 6: back4
Month 6: jaw and submandibular area4
Month 6: other14
Month 12: shoulder4
Month 12: elbow2
Month 12: hip5
Month 12: knee3
Month 12: ankle or foot5
Month 12: back2
Month 12: jaw and submandibular area3
Month 12: other12
Month 18: shoulder4
Month 18: elbow1
Month 18: hip3
Month 18: knee2
Month 18: ankle or foot2
Month 18: back1
Month 18: jaw and submandibular area0
Month 18: other8
Month 24: shoulder1
Month 24: elbow0
Month 24: hip0
Month 24: knee1
Month 24: ankle or foot1
Month 24: back0
Month 24: jaw and submandibular area0
Month 24: other2
SecondaryDuration of Flare-up at Months 6, 12, 18 and 24

Duration of flare-up was defined as (date of end of flare-up - date of start of flare-up + 1).

Time frame:
Months 6, 12, 18 and 24
Reported as:
Mean · days
Duration of Flare-up at Months 6, 12, 18 and 24
daysPalovarotene
Month 6130.7 ± 153.3
Month 12121.7 ± 102.7
Month 1872.4 ± 42.6
Month 2472.3 ± 53.9
SecondaryPercentage of Participants With Extra Bone Growth at Months 6, 12, 18 and 24

Percentage of participants with at least 1 extra bone growth associated or not with a flare-up since last visit is presented.

Time frame:
Months 6, 12, 18 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Extra Bone Growth at Months 6, 12, 18 and 24
percentage of participantsPalovarotene
Month 6: associated8.5
Month 6: not associated3.4
Month 12: associated8.5
Month 12: not associated8.5
Month 18: associated1.7
Month 18: not associated3.4
Month 24: associated0
Month 24: not associated3.4

Adverse events

Collected over Adverse events and deaths were collected from signing the informed consent form (Day 1) up to 30 days post last dose, approximately 32 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palovarotene2/59 (3.4%)9/59 (15.3%)45/59 (76.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPalovarotene
PneumoniaInfections and infestations2/59
COVID-19Infections and infestations1/59
InfluenzaInfections and infestations1/59
Lower respiratory tract infectionInfections and infestations1/59
SepsisInfections and infestations1/59
Fibula fractureInjury, poisoning and procedural complications1/59
Humerus fractureInjury, poisoning and procedural complications1/59
Tibia fractureInjury, poisoning and procedural complications1/59
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/59
Lung disorderRespiratory, thoracic and mediastinal disorders1/59
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPalovarotene
Dry skinSkin and subcutaneous tissue disorders14/59
COVID-19Infections and infestations11/59
FallInjury, poisoning and procedural complications10/59
Skin abrasionInjury, poisoning and procedural complications7/59
Back painMusculoskeletal and connective tissue disorders7/59
ArthralgiaMusculoskeletal and connective tissue disorders6/59
Upper respiratory tract infectionInfections and infestations5/59
PruritusSkin and subcutaneous tissue disorders5/59
Pain in extremityMusculoskeletal and connective tissue disorders5/59
LymphoedemaVascular disorders5/59

Baseline characteristics

The full analysis set (FAS)/safety set included all participants who received at least 1 dose of palovarotene in this study.

Age, Continuous
Age, Continuous(years)Palovarotene
Mean22.4 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Palovarotene
Female28
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Palovarotene
Hispanic or Latino10
Not Hispanic or Latino33
Unknown or Not Reported16
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Palovarotene
White38
Black or African American0
Asian3
Other1
Multiple2
Not Reported15
08

Study locations

13 sites
  • University of California San Francisco (UCSF)
    San Francisco, California 94143, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Children's Hospital of Philidelphia
    Philadelphia, Pennsylvania 19104, United States
  • The Perelman School of Medicine - The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1181ACH, Argentina
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
  • Hospital Israelita Albert Einstein
    Morumbi, Sao-Paulo 05652-900, Brazil
  • Toronto General Hospital
    Toronto, M5T 2S8, Canada
  • Groupe Hospitalier Necker Enfants Malades
    Paris, 75015, France
  • Istituto Giannina Gaslini
    Genoa, 16147, Italy
  • Hospital Universitario Ramon y Cajal
    Colmenar Viejo, 28034, Spain
  • Norrlands Universitetssjukhus
    Umeå, 90737, Sweden
  • Royal National Orthopaedic Hospital
    London, HA7 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Nov 2024, 32 months.

Results were first posted in Jun 2025, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 30, 2021
StartActual
Mar 14, 2022
Primary completionActual
Nov 30, 2024
CompletionActual
Nov 30, 2024
Results first posted
Jun 13, 2025
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05027802
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Mar 14, 2022
Primary completion
Nov 30, 2024
Completion
Nov 30, 2024
Results posted
Jun 13, 2025
Last update
Jun 22, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palovarotene

Start the discussion